Boswellia serrata is a tree native to India, the Middle East, and Northern Africa whose resin has been used for centuries as a natural anti-inflammatory. You may know it better as Indian frankincense. The resin, tapped from beneath the bark, contains a group of active compounds called boswellic acids that block a specific inflammatory pathway in the body. Today it’s widely sold as a dietary supplement for joint pain, digestive conditions, and respiratory health.
The Tree and Its Resin
Boswellia serrata is a moderate to large deciduous tree in the Burseraceae family that thrives in dry, mountainous terrain. In India, the major source regions include the states of Andhra Pradesh, Gujarat, Madhya Pradesh, Jharkhand, and Chhattisgarh. The tree produces a gummy oleoresin (sometimes called “salai guggul” or “dhup”) that’s harvested by making incisions in the bark, similar to how rubber is tapped.
The raw resin is a complex mixture: 30 to 60 percent resin, 5 to 10 percent essential oils, and the remainder polysaccharides. The compounds that matter most are four pentacyclic triterpenic acids, the boswellic acids. Among these, one stands out: acetyl-11-keto-beta-boswellic acid, commonly abbreviated AKBA, which is the most potent anti-inflammatory compound in the resin.
How It Reduces Inflammation
Most over-the-counter painkillers work by blocking an enzyme called COX, which is one branch of the body’s inflammatory response. Boswellic acids take a different route. They directly inhibit an enzyme called 5-lipoxygenase (5-LOX), which produces leukotrienes, inflammatory molecules involved in chronic pain, swelling, and allergic responses. AKBA is the most effective of the boswellic acids at this, shutting down leukotriene production at very low concentrations in lab studies.
What makes this mechanism distinctive is its specificity. Researchers have confirmed that AKBA binds to a dedicated site on the 5-LOX enzyme that’s separate from where the enzyme normally interacts with its fatty acid fuel. Other similarly shaped plant compounds that lack AKBA’s particular chemical features (a keto group and a carboxyl group on specific parts of the molecule) show no inhibitory effect at all. This isn’t a blunt, nonspecific anti-inflammatory action. It’s targeted.
Because leukotrienes play a role in a wide range of inflammatory conditions, from arthritis to asthma to inflammatory bowel disease, this mechanism explains why Boswellia shows up in research across several seemingly unrelated health problems.
Joint Pain and Osteoarthritis
The strongest clinical evidence for Boswellia serrata is in osteoarthritis. A systematic review and meta-analysis pooling data from multiple randomized controlled trials found that Boswellia significantly improved pain, stiffness, and physical function compared to placebo. On standardized joint health questionnaires, people taking Boswellia scored meaningfully better across all three measures.
The benefits appear to build over time. At four weeks, pain scores improved modestly. By eight weeks, the improvement roughly doubled. At twelve weeks, the gains were larger still, suggesting that Boswellia works best with consistent, sustained use rather than as a quick fix. Stiffness followed the same trajectory, with improvements at four weeks that continued deepening through three months of use.
One placebo-controlled trial using a standardized extract (containing 30% AKBA and 50 to 55% total boswellic acids) at 600 mg per day found improvements in joint health and mobility within the first five days, though more substantial changes took longer to develop. The extract was used safely for 90 days.
Digestive and Respiratory Uses
In a clinical study of patients with moderate to severe ulcerative colitis, a Boswellia serrata preparation taken three times daily for six weeks produced remission in 82% of participants. For comparison, the standard pharmaceutical treatment (sulfasalazine) achieved remission in 75% of its group. Blood markers, stool properties, and tissue biopsies all improved. This is a single study and not enough to draw sweeping conclusions, but the results were notable enough to generate continued research interest.
For asthma, a double-blind, placebo-controlled study over six weeks found that 70% of patients taking Boswellia experienced measurable improvement. Their breathing capacity increased, the number of asthma attacks decreased, and blood markers of allergic inflammation dropped. This aligns with the 5-LOX mechanism, since leukotrienes are major drivers of airway constriction and allergic inflammation in the lungs.
How It Compares to Standard Painkillers
NSAIDs like ibuprofen and naproxen remain the most commonly used anti-inflammatory drugs, but they carry well-documented risks with long-term use, particularly gastrointestinal damage, cardiovascular problems, and kidney complications. Clinical evidence suggests Boswellia serrata extracts can achieve comparable reductions in pain and inflammation for conditions like osteoarthritis, with a considerably better safety profile.
That said, Boswellia works more slowly. If you need fast relief from acute pain, an NSAID will act within hours. Boswellia typically takes days to weeks to produce noticeable effects. For people managing a chronic inflammatory condition who want to reduce their reliance on daily painkillers, it may be a practical option worth discussing with a healthcare provider.
Dosage and What to Look For
Clinical trials have safely used Boswellia serrata extract at doses up to 1,000 mg daily for up to six months, and up to 2,400 mg daily for shorter periods of about one month. Most joint health studies use somewhere in the range of 300 to 600 mg per day of a standardized extract.
Standardization matters significantly with Boswellia supplements. The resin contains dozens of compounds, and not all of them are equally active. Some non-active triterpenes in the resin can actually compete with AKBA and reduce its effectiveness. High-quality extracts are typically standardized to contain at least 30% AKBA and 50 to 55% total boswellic acids. A supplement that simply lists “Boswellia serrata” without specifying the boswellic acid content may contain far less of the active compounds. Check the label for standardization percentages before purchasing.
Side Effects and Interactions
Boswellia serrata is generally well tolerated. The most commonly reported side effects in clinical trials are mild gastrointestinal symptoms like nausea, acid reflux, or digestive discomfort. These tend to be infrequent and typically resolve on their own.
The more important concern is drug interactions. Boswellia inhibits several liver enzymes responsible for metabolizing medications, specifically CYP2C9, CYP2C19, and CYP3A4. These enzymes process a wide range of pharmaceutical drugs. The most clinically significant interaction documented so far is with warfarin, a blood thinner. Because Boswellia slows the breakdown of warfarin, it can amplify its anticoagulant effect, raising the risk of bleeding. If you take blood thinners or any medication metabolized through these liver enzyme pathways, this is something to flag with your pharmacist or doctor before starting Boswellia.
Safety data for pregnant or breastfeeding women is insufficient, so most sources recommend avoiding use during pregnancy.